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Although the provision of antiretroviral therapy (ART) through 
the South African public health care sector has expanded 
rapidly since its inception in 2003, it has been estimated that 
less than one-quarter of those in need of antiretrovirals (ARVs) 
were on treatment by the end of 2005.1 Furthermore, the 
numbers of people requiring ART will continue to rise for the 
foreseeable future, as those currently too well to need ART join 
those continuing in the programme. 
The South African government is committed to providing 
ARVs to all who need them.2 Given the size of the epidemic, 
and the limited resources available for public health care, it 
is crucial that the most efficient models of ART provision are 
utilised in order to achieve this goal. Unfortunately, there is 
little existing information on the cost and cost-effectiveness of 
different models of ART care. This is particularly true of those 
primary and community care-based models most relevant 
to lower- and middle-income countries with generalised 
epidemics.3-5 Early cost analyses of ART provision, conducted 
in North America and Europe, focused largely on the cost of 
hospital, rather than clinic-based, care.6 However, one recent 
study7 of Swiss clinics compared hospital-based with general 
practice-based ART provision. The authors found that although 
hospital-based care was more expensive, this was almost 
entirely because of differences in ARV prescribing patterns and 
that non-medication costs did not differ significantly between 
the study arms. 
Two costing studies of middle-income countries that do 
not have generalised epidemics have been performed, viz. in 
Thailand, looking at hospital-based clinics,8 and in Mexico.9 
The latter study covered 11 major clinics nationwide, but the 
analysis abstracted away the variation due to differences in 
site of care provision via clinic fixed-effects. This made any 
consideration of cost differentials due to different models of 
care impossible. 
Almost nothing is currently known about the overall cost 
of providing ARV services through the public health care 
sector in Africa. A study from KwaZulu-Natal found that 
running a voluntary counselling and testing (VCT) clinic cost 
between $161 and $53 per client in 2002/03, falling as the 
number of clients seen rose.10 The only existing cost study of 
ART provision in South Africa of which the authors are aware, 
found that a dedicated, primary care ART clinic in Khayelitsha 
in the Western Cape cost R145.15 ($22.56) per visit in 2002/03, 
excluding patient-specific items such as medicines and 
laboratory tests.11 
A more recent, predominantly qualitative, comparison of 
different models of ART care provision in the Western Cape12 
noted the significant variations in staff costs across clinics 
depending on whether they operated at hospitals or primary 
health care facilities, and on the mix of clinical staff. 
This study aimed to provide information on the operating 
costs of a doctor- and adherence counsellor-intensive clinic 
based in the Western Cape. The objectives of the analysis were 
first to measure the cost components of a dedicated ART clinic 
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Background. The provision of antiretroviral therapy (ART) is 
being rolled out across South Africa. Little evidence exists on 
the cost of running clinics for ART provision. 
Objectives. To determine the cost per patient-month enrolled 
in an ART programme and per patient-visit for a dedicated, 
public-sector ART clinic in a South African peri-urban setting 
in 2004/05 and 2005/06, as the clinic moved from a temporary 
to a permanent site. 
Methods. A retrospective costing study was performed from a 
programme perspective. Two years of expenditure data for the 
clinic were collected from primary sources. Costs per patient 
visit and per patient-month were calculated in Rand and 
converted to 2004 US$ (R6.4347 = US$1). 
Results. The total cost of running the site, excluding patient-
specific items (medicines and medical tests), was $174 072 in 
2004/05 and $421 872 in 2005/06. Cost per patient-month fell 
from $40.29 to $36.47, a 9% decrease; cost per patient-visit fell 
from $54.79 to $41.62, a 24% decrease. In 2005/06, 68% of all 
expenditure was on medical and pharmacy staff (versus 62% 
in 2004/05), 23% was on the employment of peer adherence 
counsellors (versus 35%), and the remaining 9% was on capital 
costs and supplies (versus 3%). 
Conclusions. The increase in scale of operation for the 
provision of ART at this clinic allowed economies of scale to 
be reaped. Staff costs, both medical and support, comprised 
the large majority of total clinic costs, such that the erection 
of a dedicated building for the clinic had little impact on the 
economic cost of care. 
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in South Africa, and second to determine how the importance 
of these components varied as the clinic grew in size. It is 
hoped that this will contribute to a fuller understanding of the 
likely evolution of the cost of providing ART as the national 
treatment programme expands. 
Methods 
Site description 
The site studied, the Hannan Crusaid Treatment Centre 
(HCTC), is a dedicated ART clinic based at the Gugulethu Day 
Hospital in Nyanga, a peri-urban settlement close to Cape 
Town. Operating since September 2002 it was initially a joint 
project between the Desmond Tutu HIV Centre (DTHC), which 
is a not-for-profit HIV research organisation; the UK-based 
charity Crusaid; and the provincial government of the Western 
Cape (PGWC). It has subsequently been fully integrated into 
the provincial ART roll-out programme. The HCTC acts as the 
primary care provider to all individuals enrolled at the centre, 
providing ART and non-ART-related care. The work of the 
HCTC has been described previously.13 
This study was conducted retrospectively covering the 2 
financial years 2004/05 and 2005/06, from March 2004 to 
February 2006. At the beginning of the observation period the 
clinic was run from a temporary structure with 70 m2 of floor 
space, in the grounds of the Gugulethu Day Hospital. In March 
2005 the clinic relocated to a purpose-built clinic, 369 m2 in size, 
on the same site. A wide range of medical and non-medical 
equipment was purchased for this new clinic. 
All medical staff are employed by the PGWC. In March 2004 
the staff consisted of 1 principal medical officer (PMO) and 1 
professional nurse (PN). Two years later this had expanded 
to include 3 PMOs, 2 senior medical officers, 2 PNs, a staff 
nurse, a principal pharmacist and 2 assistant pharmacists. A 
unit manager was also employed during some of the period in 
question. 
The Sizophila adherence counsellor programme is a peer-
counselling project that has been an integral part of the HCTC 
ART programme since its inception. Counsellors are employed 
from the local community and are all openly living with HIV. 
Each counsellor is responsible for up to 50 patients, providing 
pre-treatment counselling, group education on living on ART, 
home visits to monitor adherence and ongoing treatment 
support. This support is intensified if ART adherence declines. 
The project is co-ordinated by a nurse employed by the DTHC 
and during the period of study utilised a cellphone-based 
reporting system for relaying messages and reporting ART pill 
counts from home visits. 
Data collection and analysis 
The cost analysis was performed retrospectively from a 
programme perspective. The cost of the buildings and their 
contents were sourced from receipts for the relevant items 
provided by the DTHC and PGWC. Costs were apportioned 
across all years of useful lifetime: the temporary building 
was assumed to have a lifetime of 10 years, the purpose-
built building 30, the fixtures and fittings 5, and electronic 
equipment 3. All costs were discounted at 3%, in line with 
international standards.14 
The monthly cost of employing medical staff was taken 
from PGWC wage rates in February 2006. The costing of the 
Sizophila was complicated by the programme being managed 
from the DTHC by the nurse co-ordinator. The cost of running 
her office at the DTHC was included in proportion to her time 
spent on Sizophila. The cost of developing, implementing 
and running the cellphone-based reporting system was also 
included. 
The quantity of medical supplies, such as needles, gloves 
and thermometers, and of cleaning products used in 2005/06 
by the centre, was estimated by the nurse in charge of ordering 
such items. The cost of these items was calculated from the 
PGWC medical depot catalogue. A cost per visit for those 
supplies was calculated and that cost attributed to 2004/05 
visits. 
Stationery for patient records was provided by the DTHC. 
This cost was calculated from receipts for all items except 
paper forms, for which costs were based on the number of 
sheets of paper used per visit multiplied by the cost of the 
paper and of photocopying. 
All costs were standardised to average 2004 prices using 
South Africa’s consumer price index.15 Costs were then 
converted into US dollars using the average exchange rate for 
2004 at the rate of US$1 to R6.4347.16 Total costs were calculated 
by summing all categories. The total number of visits for each 
financial year, both scheduled and unscheduled, was taken 
from clinic records. The total number of patient-months was 
calculated by measuring the number of days each patient 
who enrolled at the HCTC before 1 March 2006 spent in the 
programme in each financial year, and dividing the total by 28. 
Results 
The total cost of running the HCTC rose by 142% from $174 072 
in 2004/05 to $421 872 in 2005/06 (Table I). The total number 
of patient visits made in the 2005/06 financial year was 10 137, 
an increase of 219% over 2004/05, although the total number of 
patient-months on treatment rose by only 167%, from 4 321 to 
11 569. 
The move from a temporary structure to a purpose-built 
building meant that the annual economic cost of the centre’s 
building and equipment rose more than eightfold from 
$3 075 to $29 221, far faster than the rate of increase in patient 
numbers. However, even in 2005/06 physical assets accounted 
for only 6.2% of total costs. 
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In contrast, the cost of the counselling programme rose more 
slowly than patient growth, increasing by 60% between the 
2 years. As a result, the proportion of clinic costs due to this 
programme fell from 34.9% in 2004/05 to 23.0% in 2005/06. 
The largest cost component at the clinic was that of clinical 
and managerial staff, which rose from $287 829 to $693 785 
over the period of observation. This accounted for 61.9% of 
all costs in 2004/05, rising to 68.2% in 2005/06. More than 
three-fifths (62.0%) of this cost in the more recent year was due 
to doctors’ salaries, with the remainder being split between 
nurses (14.3%), pharmacists (17.5%) and a unit manager (6.1%). 
The cost per patient visit fell by 24.0% between the 2 years 
of observation, from $54.79 to $41.62 (Fig. 1). Although the 
proportion of costs attributable to physical assets rose, it 
had little impact on the overall cost per patient-month. More 
noticeable was the fall in the proportion attributable to the 
adherence counsellor programme. The cost per patient-month 
changed little between 2004/05 and 2005/06, falling from 
$40.29 to $36.47 (Fig. 2). 
Discussion 
The reduction in cost per patient visit seen at this clinic over 
the period of observation, as services were rapidly scaled-up, 
suggests that there are significant potential returns to clinic 
scale in the provision of ARVs. Evidence that the clinic’s 
clinical outcomes were not affected by this scale-up,13 suggests 
that the reduction in cost per patient seen is not due to a 
reduced standard of care. The smaller reduction in cost per 
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Figure 1: Cost per Patient Visit of Hannan Crusaid Treatment Centre 
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Fig. 1. Cost per patient visit (US$) at the Hannan Crusaid Treatment 
Centre.
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Fig. 2. Cost per patient-month (US$) at the Hannan Crusaid Treatment 
Centre.
Table I. Cost components at the Hannan Crusaid Treatment Centre (2004 US$)
                    2004/05                         2005/06 
Physical assets 
Building         2 636    22 993 
Fixtures and fittings          439      2 991 
Electronic hardware              -      3 236 
Medical staff  
Doctors’ salaries       82 427                 178 540 
Nurses’ salaries       22 903    41 196 
Pharmacists’ salaries        2 489                   50 423 
Office manager’s salary               -                   17 670 
Sizophila Counselling Programme 
Management and administration     15 152    15 788 
Counsellor salaries                     36 447   72 102 
Cellphone-based reporting system       9 115      9 412 
Supplies and overheads 
Medical supplies         1 086     3 466 
Stationery            998     2 763 
Overheads            381     1 484 
Total cost*                     174 072                421 872 
Number of patient-visits        3 177   10 137 
Cost per visit         54.79     41.62 
Number of patient-months on treatment      4 321     1 569 
Cost per patient-month on treatment       40.29     36.47 
*Figures do not sum precisely because of rounding.
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patient-month can be attributed to the rise in the proportion 
of patients who were newly enrolled at the clinic, since clinic 
visits are more frequent in the first 6 months of care than 
thereafter. 
The cost of running the HCTC was largely driven by staff 
salaries. This is in line with evidence from other South African 
studies that medical staff costs make up the majority of non-
patient-specific expenditures at ARV clinics.11 Unlike most 
other ARV clinics in South Africa, the HCTC is a heavily 
doctor-based programme,12 which has the effect of raising the 
overall cost per visit well above that seen at another peri-urban 
clinic in the Western Cape.11 The expansion in spending on staff 
salaries at the HCTC in this study period was proportional 
to the expansion in patient-months on treatment, but was 
slower than the rise in visits made, suggesting that some slight 
economies of scale may be achievable for medical staff. 
An unusual aspect of the HCTC programme is the heavy use 
made of community-based adherence counsellors. The number 
of counsellors, even on a per-patient basis, is far higher than 
in comparable clinics across the Western Cape.12 In March 2004 
the counselling programme had been growing rapidly since its 
inception 18 months previously. It continued to expand, at a 
reduced rate, throughout the period of study. 
Economies of scale in respect of training and administration 
were seen as the programme grew. This suggests that an 
intensive counselling intervention, such as the Sizophila 
model, is likely to be most efficient in large clinics, or when 
administration is shared between multiple sites. 
The limitations of this study arise largely from the limited 
scope of enquiry made. No attempt was made to consider 
the effect of scale on demand for patient-specific items at the 
clinic, although it is likely that they remained approximately 
level on a per-visit basis. More importantly, no attempt was 
made to quantify what change, if any, was seen in the cost of 
care at other levels of care within the health care system; lower 
expenditure on primary care might have led to more secondary 
or tertiary care visits. 
The HCTC ARV programme is a human resource-intensive 
one, employing more doctors and more counsellors per 
patient than other models of ARV care.12 Nevertheless, 
significant economies of scale were reaped from expanding 
the programme between 2004 and 2006, particularly from the 
adherence counsellor component, without affecting clinical 
performance. Increased clinic scale appears to offer cost 
benefits in the South African ART roll-out. 
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